ACT Brief: Ultra-Compressed CNPV Review Timelines, New IgAN Therapy Approval, and Smarter Clinical Reference Data Strategies

In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission readiness, review the FDA’s accelerated approval of Voyxact for IgA nephropathy, and explore new insights from the Veeva R&D and Quality Summit on modernizing clinical reference data management.